 |
|
|
| |
Strong intrahepatic decline of hepatitis D virus RNA and antigen after 24 weeks of treatment with Myrcludex B in combination with Tenofovir in chronic HBV/HDV infected patients: Interim results from a multicenter, open-label phase 2b clinical trial
|
| |
| |
Reported by Jules Levin
EASL 2018 April 11-15 Paris France
Lena Allweiss, Claudia Dettmer, Tassilo Volz, Katja Giersch, Alexander Alexandrov, Heiner Wedemeyer, Stephan Urban, Jan-Hendri Bockmann, Marc Lutgehetmann, Maura Dandri
EASL: Final results of a multicenter, open-label phase 2b clinical trial to assess safety and efficacy of MyrcludexB in combination with Tenofovirin patients with HBV/HDV coinfection - (05/01/18)
|
| |
|
|
|
|
|
